REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $38K invested in REGENERX BIOPHARMACEUTICALS in 2018 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
6% more capital invested
Capital invested by funds: $36K → $38K (+$2K)
0% more funds holding
Funds holding: 2 → 2 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
-$8.59K |
RGN Hedge Fund Activity: Q1 2018 in Review
2 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2018, worth a combined $38K — up 5.6% from $36K a quarter earlier.
Fund positioning in RGN was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Dumont & Blake Investment Advisors, cutting an estimated $8.59K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $38K of REGENERX BIOPHARMACEUTICALS stock for Q1 2018, up 5.6% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2018 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q1 2018 was Dumont & Blake Investment Advisors, an estimated $8.59K sold.
Based on aggregated 13F filings for Q1 2018.